X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (217) 217
oncology (202) 202
humans (198) 198
breast cancer (196) 196
female (183) 183
middle aged (141) 141
adult (109) 109
aged (107) 107
breast neoplasms - drug therapy (96) 96
breast neoplasms - pathology (95) 95
medicine & public health (83) 83
cancer (76) 76
chemotherapy (57) 57
surgical oncology (56) 56
breast neoplasms - genetics (54) 54
metastasis (54) 54
research (49) 49
treatment outcome (49) 49
surgery (48) 48
antineoplastic combined chemotherapy protocols - therapeutic use (47) 47
care and treatment (47) 47
cancer research (43) 43
women (41) 41
chemistry (40) 40
therapy (40) 40
breast neoplasms - mortality (39) 39
metallurgy (38) 38
risk factors (38) 38
compounds thereof (34) 34
disease-free survival (34) 34
inorganic chemistry (34) 34
non-metallic elements (34) 34
neoplasm staging (33) 33
postmenopausal women (33) 33
prognosis (32) 32
breast neoplasms - metabolism (31) 31
obstetrics & gynecology (31) 31
health aspects (30) 30
oncology, experimental (30) 30
trastuzumab (30) 30
analysis (29) 29
case-control studies (29) 29
japan (29) 29
adjuvant treatment (27) 27
breast neoplasms - surgery (27) 27
clinical trials (27) 27
estrogen (27) 27
expression (27) 27
receptor, erbb-2 - metabolism (27) 27
tumors (27) 27
survival (26) 26
aged, 80 and over (25) 25
epidermal growth factor (24) 24
genetic aspects (24) 24
trial (24) 24
cancer patients (23) 23
docetaxel (23) 23
genetic predisposition to disease (22) 22
tamoxifen (22) 22
diagnostic radiology (21) 21
neoplasm metastasis (21) 21
patients (21) 21
antimitotic agents (20) 20
antineoplastic agents (20) 20
antineoplastic combined chemotherapy protocols - adverse effects (20) 20
endocrine therapy (20) 20
metastases (20) 20
neoadjuvant therapy (20) 20
breast neoplasms - epidemiology (19) 19
cancer therapies (19) 19
imaging / radiology (19) 19
interventional radiology (19) 19
chemotherapy, adjuvant (18) 18
drug administration schedule (18) 18
drug therapy (18) 18
genotype (18) 18
original (18) 18
receptors, estrogen - metabolism (18) 18
article (17) 17
breast neoplasms - chemistry (17) 17
carcinoma (17) 17
genetics (17) 17
medical research (17) 17
womens health (17) 17
erbb-2 protein (16) 16
estrogen-receptor (16) 16
genetics & heredity (16) 16
genome-wide association (16) 16
metastatic breast cancer (16) 16
polymorphism, single nucleotide (16) 16
postmenopause (16) 16
receptor, erbb-2 - analysis (16) 16
risk (16) 16
cyclophosphamide - administration & dosage (15) 15
genome-wide association study (15) 15
receptors, estrogen - analysis (15) 15
survival analysis (15) 15
asian continental ancestry group (14) 14
capecitabine (14) 14
combination (14) 14
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 10/2017, Volume 28, Issue suppl_9
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2015, Volume 26, Issue suppl 7, pp. vii11.3 - vii11
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 3, pp. 209 - 219
In women with hormone-receptor–positive metastatic breast cancer that had progressed after endocrine therapy, palbociclib plus fulvestrant was associated with... 
TARGET | MEDICINE, GENERAL & INTERNAL | THERAPY | FULVESTRANT | CLINICAL-TRIALS | CYCLIN D | RESISTANCE | MUTATIONS | COMBINATION | ESTROGEN-RECEPTOR | 4/6 INHIBITOR PALBOCICLIB | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Estradiol - analogs & derivatives | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Protein Kinase Inhibitors - adverse effects | Receptors, Progesterone - analysis | Pyridines - adverse effects | Aged, 80 and over | Estradiol - adverse effects | Adult | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Pyridines - therapeutic use | Double-Blind Method | Estradiol - therapeutic use | Biomarkers - analysis | Piperazines - therapeutic use | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Aged | Receptor, ErbB-2 - analysis | Women | Hormone receptors | Care and treatment | Usage | Breast cancer | Diagnosis | Health aspects | Thrombocytopenia | Leukopenia | Endocrine therapy | Fatigue | Metastasis | Cancer therapies | Cyclin-dependent kinase 4 | Fulvestrant | Metastases | Epidermal growth factor | Womens health | S phase | Cell cycle | Neutropenia | G1 phase | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 425 - 439
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 904 - 916
Summary Background Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark of endocrine therapy-resistant, hormone receptor-positive breast... 
Hematology, Oncology and Palliative Medicine | HETEROGENEITY | WOMEN | PALBOCICLIB | THERAPY | EXEMESTANE | ONCOLOGY | MUTATION | RESISTANCE | COMBINATION | AROMATASE INHIBITORS | PI3K INHIBITOR | Estradiol - analogs & derivatives | Humans | Middle Aged | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Receptors, Estrogen - analysis | Fulvestrant | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Neoplasm Metastasis | Hyperglycemia - chemically induced | DNA, Neoplasm - blood | DNA Mutational Analysis | Exanthema - chemically induced | Postmenopause | Female | Morpholines - adverse effects | Aminopyridines - administration & dosage | Drug Eruptions - etiology | Double-Blind Method | Morpholines - administration & dosage | Estradiol - administration & dosage | Survival Rate | Signal Transduction - genetics | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Retreatment | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Aspartate Aminotransferases - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Clinical trials | Product development | Breast cancer | Postmenopausal women | Hormones | Antineoplastic agents | Analysis | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 367 - 377
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2014, Volume 25, Issue suppl_5, pp. v31 - v31
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 22, pp. 2108 - 2121
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 4, pp. 345 - 352
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 10/2017, Volume 44, Issue 10, p. 831
Oligometastases means the state which the anatomy and physiology may limit or concentrate metastases to a single or a limited number of organs. In patients... 
Breast Neoplasms - therapy | Neoplasm Metastasis | Clinical Trials as Topic | Biopsy | Breast Neoplasms - pathology | Humans
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2147 - 2159
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 20, pp. 1926 - 1936
Journal Article
by Michailidou, Kyriaki and Hall, Per and Gonzalez-Neira, Anna and Ghoussaini, Maya and Dennis, Joe and Milne, Roger L and Schmidt, Marjanka K and Chang-Claude, Jenny and Bojesen, Stig E and Bolla, Manjeet K and Wang, Qin and Dicks, Ed and Lee, Anew and Turnbull, Clare and Rahman, Nazneen and Fletcher, Olivia and Peto, Julian and Gibson, Lorna and dos Santos Silva, Isabel and Nevanlinna, Heli and Muranen, Taru A and Aittomäki, Kristiina and Blomqvist, Carl and Czene, Kamila and Irwanto, Astrid and Liu, Jianjun and Waisfisz, Quinten and Meijers-Heijboer, Hanne and Adank, Muriel and van der Luijt, Rob B and Hein, Rebecca and Dahmen, Norbert and Beckman, Lars and Meindl, Alfons and Schmutzler, Rita K and Müller-Myhsok, Bertram and Lichtner, Peter and Hopper, John L and Southey, Melissa C and Makalic, Enes and Schmidt, Daniel F and Uitterlinden, Ane G and Hofman, Albert and Hunter, David J and Chanock, Stephen J and Vincent, Daniel and Bacot, François and Tessier, Daniel C and Canisius, Sander and Wessels, Lodewyk F. A and Haiman, Christopher A and Shah, Mitul and Luben, Robert and Brown, Judith and Luccarini, Craig and Schoof, Nils and Humphreys, Keith and Li, Jingmei and Nordestgaard, Børge G and Nielsen, Sune F and Flyger, Henrik and Couch, Fergus J and Wang, Xianshu and Vachon, Celine and Stevens, Kristen N and Lambrechts, Diether and Moisse, Matthieu and Paridaens, Robert and Christiaens, Marie-Rose and Rudolph, Anja and Nickels, Stefan and Flesch-Janys, Dieter and Johnson, Nichola and Aitken, Zoe and Aaltonen, Kirsimari and Heikkinen, Tuomas and Broeks, Annegien and van 't Veer, Laura J and van der Schoot, C. Ellen and Guénel, Pascal and Truong, Thérèse and Laurent-Puig, Pierre and Menegaux, Florence and Marme, Frederik and Schneeweiss, Aneas and Sohn, Christof and Burwinkel, Barbara and Zamora, M. Pilar and Perez, Jose Ignacio Arias and Pita, Guillermo and Alonso, M. Rosario and Cox, Angela and Brock, Ian W and Cross, Simon S and Reed, Malcolm W. R and Sawyer, Elinor J and Tomlinson, Ian and Kerin, Michael J and Miller, Nicola and Henderson, Brian E and ... and kConFab Investigators and GENICA Gene Environm Interaction B and Hereditary Breast Ovarian Canc Res and Australian Ovarian Can Study Grp and Breast Ovarian Canc Susceptibility and Australian Ovarian Cancer Study Group and GENICA (Gene Environment Interaction and Breast Cancer in Germany) Network and Breast and Ovarian Cancer Susceptibility Collaboration and Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) and The Breast and Ovarian Cancer Susceptibility Collaboration and The GENICA (Gene Environment Interaction and Breast Cancer in Germany) Network
Nature genetics, ISSN 1061-4036, 2013, Volume 45, Issue 4, pp. 353 - 361
Journal Article